Abstract
AimAppropriate management of a diabetic patient with co-morbidities, who is willing to fast during Ramadan. Case presentation A 45 year old male patient with T2DM for 5 years, current A1c of 8.3% and other co-morbidities is currently treated with metformin 500mg BID and glimepiride 2mg. During the pre-Ramadan assessment, glimepiride 2mg was changed to extended release gliclazide 60mg. It resulted in an improvement in his glycemic and microalbuminuria status without any hypoglycemic episodes. ConclusionAppropriate risk stratification with medication adjustment and Ramadan-specific diabetes education are the important aspects of T2DM management in patients willing to fast during Ramadan.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
